How the frailty score help guide treatment of older multiple myeloma patients
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz
What role will minimal residual disease testing play in multiple myeloma?
Myeloma 2016: Panel discussion on in vivo drug screening
Caroline Heckman et al.